Presence of both positive amyloid and tau biomarkers in a patient with late-onset epilepsy with otherwise unknown etiology may be sufficient to categorize patients as demonstrating epileptic preclinical AD or epileptic prodromal AD. Here, MAPT is linked to Alzheimer disease.